Over 30 years of the experience in research, drug development and management in domestic and international biotechnological and pharmaceutical companies

Served as the chief scientist of Jiangsu Hansoh, Jiangsu Hengrui and other companies

Hold a Ph.D. from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences; Research Scholar of the Max Planck Institute, Germany; Postdoctoral Fellow at the institute for Biomedical Research of University of Texas at Austin

Led the development of Hengrui G-CSF (Thiofilgrastim), Hansoh long-acting GLP-1 (Polyethylene Glycol Loxenatide), Hansoh long-acting EPO (Pegmolesatide); responsible for the IND application of Hengrui PD-1 antibody (Camrelizumab)

Technical and management expertise: protein biochemistry, protein modification, biochemical analysis, regulatory affairs, drugs manufacture validation and product launch, domestic and international cooperation, etc.; extensive experience in project management and R&D team building and management

Over 30 years of research, drug development and management experience in domestic and international biotechnology companies

Established Jiangsu Hengrui Biomedical Research Institute and served as the first director

Established Furen Ruihui Biomedical Research Institute and served as the president of the institute.Led the development of long-acting coagulation factor projects

Holds a Ph.D., Molecular Biology and Biochemistry, Concordia University, Canada; received Jiangsu Provincial "Double Innovation" Talent Award, Zhengzhou "Talent Spotting Program, Innovation Shortage Talent Award” in Henan

Led the development of pilot scale-up, production plant construction and process validation for Hengrui G-CSF (mecapegfilgrastim) project

Technical and management expertise: molecular biology, protein chemistry, cell biology, immunology, and protein drug pilot-scale testing, scale-up, and drug manufacturing volume reporting; extensive experience in project management and R&D team building and management

Over 15 years of experience in healthcare, multinational pharmaceutical companies and renowned investment institutions; Worked at Shanghai Red House Hospital, Shanghai Quyang Hospital, Anxin Insurance, Bristol Myers Squibb, IDG Capital, involving clinical, hospital management, medical insurance management, pharmaceuticals and venture capital

Hold a Master's degree in Clinical Medicine from Fudan University and a double degree MBA from Fudan University/National University of Singapore

Served as the Director of Specialty Drug Line Strategy at Bristol Myers Squibb, responsible for product line strategy, new product launch and external business development (BD)

Served as the Executive Director in the Healthcare Group of IDG Capital, responsible for biopharmaceutical investments in Gensciences, HiFiBiO, Minghui Pharmaceutical, Shanghai Model Organisms, Dingtai Group, Taichu Group, Allorion Therapeutics, and Neukio Biotherapeutics, and participated in investment in Kelun Biotech, Vitalgen, and Sciwind

Over 20 years of experience in capital and financial work

Chartered Financial Analyst (CFA) and Qualified Lawyer in China

M.A., Peking University Law School; M.A., EUROMED Business School, France

Ph.D. in Cell Biology from the University of Science and Technology of China, over 15 years of experience in the development of new large molecule protein-based drugs

Worked at Jiangsu Hengrui and Furen Ruihui, engaged in process development of recombinant proteins expressed by mammalian cells, and served as head for multiple projects

Currently serving as the head of Zhengzhou R&D Center, responsible for the CMC studies of the ongoing projects within the Group

Over 20 years of experience in new drug development in China, with rich experience in team management and clinical development

Led the project team of Pfizer China R&D Center to register and launch multiple well-known products

Led the clinical development platform of Juventas, advancing the core products to the first place in China and driving the company to become a leading cell therapy company

With 20 years of experience in R&D and production of biopharmaceuticals, led and completed more than ten innovation projects at national and provincial levels, and applied for more than 40 patents as the main inventor

Led the completion of the construction of Tianci International Innovative Drug Industry Base, with a total investment of 2 billion yuan. Pioneered the first shared pharmaceutical industry model in China

Received Shanghai Science and Technology Progress Award by the Shanghai Municipal People's Government. Honored as the Outstanding Innovation and Entrepreneurial Talent in Zhangjiang National Innovation Demonstration Zone, among other personal honors

Nearly 20 years of experience in quality management of biopharmaceutical production, with the bioreactors operated by the biotech companies served put into commercial operation for more than 40,000 liters

Proficient in building and maintaining quality systems throughout the life cycle of product development, clinical trials, technology transfer, and commercialization, with experience in successfully launching proprietary products and CMO products